First patient enrolled in new SER-252 trial for advanced Parkinson’s disease

Feb 24, 2026

Study will evaluate safety, tolerability, and pharmacokinetics

Written by Andrea Lobo | February 23, 2026

  • A Phase 1b trial of SER-252 (POZ-apomorphine) in advanced Parkinson’s disease has enrolled its first patient.
  • SER-252 is designed to reduce “off” episodes by providing continuous dopaminergic stimulation.
  • The trial is evaluating safety and early efficacy, and the therapy is designed for subcutaneous self-administration.

A Phase 1b clinical trial evaluating Serina Therapeutics’s SER-252 (POZ-apomorphine) in people with advanced Parkinson’s disease has enrolled its first patient, the company announced.

The global registrational trial is evaluating the treatment’s safety, tolerability, pharmacokinetics, and preliminary efficacy. The first group of participants is being enrolled in Australia, where the company has an operational presence. Serina said it expects to begin dosing in the first quarter and plans to provide updates as enrollment progresses.

Phase 1b study designed to support regulatory development

Serina said the trial is intended to generate data to support future regulatory submissions.

“Enrolling our first patient represents an important operational milestone as we advance SER-252 into the clinic,” Steve Ledger, Serina’s CEO, said in a company press release. “Our team has built a strong operational presence in Australia, working closely with leading Parkinson’s disease specialists and patient advocacy organizations to support efficient enrollment.”

Serina has said it plans to pursue SER-252 through the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway, which allows companies to rely in part on data from previously approved drugs.

Parkinson’s disease is caused by the progressive loss of dopaminergic neurons, the nerve cells that produce dopamine, a chemical messenger the brain uses to coordinate movement. Levodopa is a mainstay treatment that helps ease motor symptoms by providing a precursor molecule the body converts into dopamine.

However, long-term levodopa use can cause side effects such as dyskinesia, or involuntary movements, and many patients experience “off” episodes, periods of reduced symptom control that occur between doses.

Read more here: First patient enrolled in new SER-252 trial for advanced Parkinson’s disease